The discovery and development of boceprevir

Bibliography

• Choo QL, Kuo G, Weiner AJ, et al. Isolation of a DNA clone from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
   PubMed Web of Science ®Google Scholar
• Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4
   PubMed Web of Science ®Google Scholar
• WHO fact sheet. 2012. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
   Google Scholar
• Qiu P, Cai X-Y, Ding W, et al. HCV genotyping using statistical classification approach. J Biomed Sci 2009;16:62-71
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchinson JG, Gordon SC. Peg interferon alfa02b plus ribavirin compared with interferon alfa-2b for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison JG, Goodman ZD. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C. Hepatology 2000;31:211-8
   PubMed Web of Science ®Google Scholar
• Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery. Antiviral Res 2009;81:6-15
   PubMed Web of Science ®Google Scholar
• Tomei L, Failla C, Santolini E. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993;67:4017-26
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Ahlborn-Laake L, Mous J. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type protease required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993;67:3835-44
   PubMed Web of Science ®Google Scholar
• McCoy MA, Senior MM, Gesell JJ, et al. Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex. J Mol Biol 2001;305:1099-110
   PubMed Web of Science ®Google Scholar
• Lemke CT, Goudreau N, Zhao S, et al. Combined X-ray, NMR and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335. J Biol Chem 2011;286:11434-43
   PubMed Web of Science ®Google Scholar
• Saalau-Bethell SM, Woodhead AJ, Chessari G, et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protease function. Nat Chem Biol 2012;8:920-5
   PubMed Web of Science ®Google Scholar
• Zhang R, Beyer BM, Durkin J, et al. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal Biochem 1999;270:268-75
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R, 5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-2(S)-[[[1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006;49:6074-86
   PubMed Web of Science ®Google Scholar
• Arasappan A, Njoroge FG, Chan T-Y, et al. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency. Bioorg Med Chem Lett 2005;15:4180-4
   PubMed Web of Science ®Google Scholar
• Bogen SL, Ruan S, Liu R, et al. Depeptidization efforts on the P3-P2' a-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity. Bioorg Med Chem Lett 2006;16:1621-7
   PubMed Web of Science ®Google Scholar
• Bogen SL, Arasappan A, Bennett F, et al. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 2006;49:2750-7
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in human infected with hepatitis C virus. Nature 2003;426:186-9
   PubMed Web of Science ®Google Scholar
• McGeary RP, Fairlie DP. Macrocylic peptidomimetics: potential for drug development. Curr Opin Drug Discov Dev 2003;1:208-17
   Google Scholar
• Chen KX, Njoroge FG, Arasappan A, et al. Novel potent hepatitis C virus NS3 protease inhibitors derived from proline-based macrocycles. J Med Chem 2006;49:995-1005
   PubMed Web of Science ®Google Scholar
• Chen KX, Njoroge FG, Vibulbhan B, et al. Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity. Angew Chem Int Ed Eng 2005;44:7024-8
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Velazquez F, Wu W, et al. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C NS3 protease. J Med Chem 2009;52:336-46
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peg interferon alfa 2b and ribavirin in treatment naïve patients with genotype1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre phase 2 trial. Lancet 2010;376:705-16
   PubMed Web of Science ®Google Scholar
• Ogert RA, Howe JA, Vierling JM, et al. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon–α2b and ribavirin in patients with chronic hepatitis in the SPRINT-1 trial. Antivir Ther 2013;18:387-97
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. New Eng J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic hepatitis C genotype 1 infection. New Eng J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Silva MO, Treitel M, Graham DJ, et al. Antiviral activity of boceprevir monotherapy in treatment-naïve subjects with chronic hepatitis C genotype 2/3. J Hepatol 2013;59:31-7
   PubMed Web of Science ®Google Scholar
• Boceprevir label information
   Google Scholar
• Kieran J, Schmitz S, O'Leary A, et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis 2013;56:228-35
   PubMed Web of Science ®Google Scholar